RAS genes (HRAS, KRAS, and NRAS) comprise the most frequently mutated oncogene
family in human cancer. With the highest RAS mutation frequencies seen with the top three …

Despite more than three decades of intensive effort, no effective pharmacological inhibitors
of the RAS oncoproteins have reached the clinic, prompting the widely held perception that …

Immune evasion is a hallmark of KRAS-driven cancers, but the underlying causes remain
unresolved. Here, we use a mouse model of pancreatic ductal adenocarcinoma to inactivate …

Cancer cells that express oncogenic alleles of RAS typically require sustained expression of
the mutant allele for survival, but the molecular basis of this oncogene dependency remains …

Oncogenic KRAS mutation is the signature genetic event in the progression and growth of
pancreatic ductal adenocarcinoma (PDAC), an almost universally fatal disease. Although it …

RAS proteins are small GTPases known for their involvement in oncogenesis: around 25%
of human tumors present mutations in a member of this family. RAS operates in a complex …

The phosphatidylinositol 3-kinase (PI3K) signaling axis impacts on cancer cell growth,
survival, motility, and metabolism. This pathway is activated by several different mechanisms …

The high frequency of phosphoinositide 3-kinase (PI3K) pathway alterations in cancer has
led to a surge in the development of PI3K inhibitors. Many of these targeted therapies are …

The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway regulates multiple cellular
processes. An overactivation of the pathway is frequently present in human malignancies …

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the
United States with a median survival of< 6 mo and a dismal 5-yr survival rate of 3%–5%. The …